You are about to leave DOPTELET.com/itp and go to an external page.
Please note that Sobi, Inc. is not responsible for the content of the website you are
about to visit.
Go back
You are about to leave DOPTELET.com/itp and go to an external page.
Please note that Sobi, Inc. is not responsible for the content of the website you are
about to visit.
Go back
Discover the Doptelet Copay
Assistance Program
Terms and Conditions
Living with low platelet counts in chronic immune thrombocytopenia is hard, but managing chronic ITP with a TPO-RA medication doesn‘t have to be.
Having an open and honest conversation with your doctor can help lead to care that best fits all your needs.
Have other treatments not worked well enough for you? Is chronic ITP impacting your day-to-day life? Here are a few questions to ask yourself before starting the conversation with your doctor:
Everyone has their own likes and dislikes, which can affect the treatment you and your doctor choose together.
Certain chronic ITP treatments require injections for dosing or food-type restrictions [like restrictions on dairy or iron supplements] that may disrupt your routine.
It‘s important to consider all of your options when choosing a treatment, including how it fits into your work schedule, ease of travel, and if you can afford it.
playing: false
Tammy, a real patient on Doptelet, has asked her doctor many questions over the years and wants to share helpful questions to ask your doctor about setting treatment goals.
playing: false
Working with your doctor can help raise your chances of finding a treatment that fits your needs and goals. Be sure to take advantage of this guide that may support you in having those important conversations with your doctor.
Sign up to access tips and tools for managing ITP—plus, a surprise shipped to your doorstep!
SIGN ME UPLet us help connect you to our financial assistance options and resources for adults with chronic ITP.
ITP SUPPORT & RESOURCESINDICATION & IMPORTANT SAFETY INFORMATION
What is DOPTELET (avatrombopag)?
DOPTELET is a prescription medicine used to help treat low blood platelet counts in adults with chronic immune thrombocytopenia (ITP) when other treatments have not worked well enough. It is not known if DOPTELET is safe or works in children.
Who should not receive DOPTELET?
You should not receive DOPTELET if you have ever had a blood clot, are pregnant, plan to become pregnant or plan to breastfeed. It is not known if DOPTELET passes into breast milk or if DOPTELET may have unintended side effects for your unborn baby. Do not breastfeed during your treatment with DOPTELET and for at least 2 weeks after the last dose.
You should call your healthcare provider or get medical help right away if you have any of the signs or symptoms of a blood clot after getting DOPTELET. They can be life threatening or cause death.
Before taking DOPTELET, you should tell your healthcare provider about all your medical conditions and medicines including vitamins, supplements, and herbal remedies.
What are the possible side effects of DOPTELET?
For patients with chronic ITP, the most common side effects are headache, fatigue, bruising, nosebleeds, upper respiratory tract infection, joint pain, bleeding gums, purple or red spots on your skin (petechiae), and runny nose.
You Should Know: These are not all of the possible side effects for DOPTELET. For more information, ask your healthcare provider or review the Prescribing Information at https://www.doptelet.com/doptelet.pdf.
If you suspect that you have experienced a side effect, call your healthcare provider. You may also report them to the US Food and Drug Administration (FDA) at 1-800-FDA-1088.
For further information, please see full Prescribing Information, including the Patient Information Leaflet.
What is DOPTELET® (avatrombopag)?
DOPTELET is a prescription medicine used to help treat low blood platelet counts in adults with chronic immune thrombocytopenia (ITP) when other treatments have not worked well enough. It is not known if DOPTELET is safe or works in children.
Who should not receive DOPTELET?
You should not receive DOPTELET if you have ever had a blood clot, are pregnant, plan to become pregnant or plan to breastfeed. It is not known if DOPTELET
What is DOPTELET (avatrombopag)?
DOPTELET is a prescription medicine used to help treat low blood platelet counts in adults with chronic immune thrombocytopenia (ITP) when other treatments have not worked well enough. It is not known if DOPTELET is safe or works in children.
Who should not receive DOPTELET?
You should not receive DOPTELET if you have ever had a blood clot, are pregnant, plan to become pregnant or plan to breastfeed. It is not known if DOPTELET passes into breast milk or if DOPTELET may have unintended side effects for your unborn baby. Do not breastfeed during your treatment with DOPTELET and for at least 2 weeks after the last dose.
You should call your healthcare provider or get medical help right away if you have any of the signs or symptoms of a blood clot after getting DOPTELET. They can be life threatening or cause death.
Before taking DOPTELET, you should tell your healthcare provider about all your medical conditions and medicines including vitamins, supplements, and herbal remedies.
What are the possible side effects of DOPTELET?
For patients with chronic ITP, the most common side effects are headache, fatigue, bruising, nosebleeds, upper respiratory tract infection, joint pain, bleeding gums, purple or red spots on your skin (petechiae), and runny nose.
You Should Know: These are not all of the possible side effects for DOPTELET. For more information, ask your healthcare provider or review the Prescribing Information at https://www.doptelet.com/doptelet.pdf.
If you suspect that you have experienced a side effect, call your healthcare provider. You may also report them to the US Food and Drug Administration (FDA) at 1-800-FDA-1088.
For further information, please see full Prescribing Information, including the Patient Information Leaflet.
This website uses cookies. By continuing to
use this website, you consent to our use of these cookies. Read more about our use of cookies